Scientists from Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences discovered a role of the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) in maintaining genomic stability, and found that PGAM1 inhibitors have the potential to expand the therapeutic benefits of Olaparib (Lynparza), an FDA-approved drug for treatment ovarian cancer, to a wider range of cancer types such as triple-negative breast cancer.
CAS news release, February 22, 2017
CAS Institute of Materia Medica discovers potential boost for Olaparib in triple-negative breast cancer